3SBio Gains Rights to Korean Cancer mAb for Emerging Countries

3SBio of Shenyang has in-licensed rights to Tanibirumab, a cancer antibody developed by PharmAbcine, a Korean biotech. Tanibirumab is a VEGFR2/KDR antibody with an anti-angiogenesis mechanism. 3SBio will own rights to the molecule for Greater China and emerging countries Thailand , Brazil and Russia . PharmAbcine was spun out of the Korea Research Institute of Bioscience and Biotechnology, a government-backed organization. More details.... Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.